List view / Grid view
A new study has identified a previously undescribed role for a type of unconventional T cell with the potential to be used in the development of new therapies for infection and cancer.
Cancer Research UK announced that four international teams are the first recipients of its global £100m Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.
7 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Patients with malignant melanoma are more likely to respond to immunotherapy treatment if they had greater diversity in their gut bacteria, according to...
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The grant for the second year of a multi-year R+D project and will be used for Hookipa’s arenaviral vector technologies, cancer immunotherapies and to...
21 September 2016 | By Abcam
PD-L1 [28-8] (ab205921) is an ideal tool to quantify PD-L1 expression in patients for PD-1 based therapies....
21 July 2016 | By SMi Group
SMi's 5th annual Cancer Vaccines event will showcase 5 key spotlight sessions on the latest advances in vaccine development and cancer therapy breakthroughs when it returns to Central London this autumn...
17 June 2016 | By Victoria White, Digital Content Producer
Cell Medica has entered into a co-development partnership with Baylor to develop technologies for engineering immune cells with enhanced functions...
13 June 2016 | By Victoria White, Digital Content Producer
Researchers have unveiled a novel radioimmunotherapy that resulted in complete remission of colorectal cancer in mouse models...
13 April 2016 | By Victoria White, Digital Content Producer
Mathematicians and physicians at the University of Bonn have developed a new model for cancer immunotherapy using mathematics...
16 March 2016 | By Victoria White
Inovio and the Wistar Institute are to research preventive and therapeutic DNA-based immunotherapies for cancers and infectious diseases...
15 March 2016 | By Victoria White
Under a collaboration with Roche, Blueprint Medicines will lead preclinical research and development through to Phase I proof of concept...
10 March 2016 | By Victoria White
PhoreMost has entered into an alliance with The Wistar Institute to identify and de-orphan novel targets in cancer, aging and the immune system...
4 March 2016 | By Victoria White
Researchers have found the tools necessary to give immunotherapy the precision guidance that patients with cancer so desperately need...
